Antidepressants (SSRIs and SNRIs) and Sex: Side Effects, Regulator Warnings and PSSD Evidence
EMA, UK MHRA and Health Canada warn on product labels that SSRI/SNRI sexual side effects can persist after stopping in some patients. Never stop abruptly—compare regulator findings and prescriber options.
Sexual side effects during treatment with selective serotonin reuptake inhibitors (SSRIs) and serotonin-noradrenaline reuptake inhibitors (SNRIs)—most commonly delayed or absent orgasm, reduced sex drive, and erectile or lubrication difficulty—are well-established in clinical trials and usually resolve after treatment stops, but drug regulators in the EU, UK, Canada and Australia now warn on product labels that in some patients sexual symptoms have continued after discontinuation. Critical safety rule first: never stop or reduce an antidepressant abruptly on your own. Sudden cessation can trigger severe antidepressant withdrawal syndrome, relapse of depression or anxiety, and suicidal thoughts—and does not prevent persistent symptoms. Any change to dose, timing or medication class should always be planned with your prescribing clinician.
Scope and method: This guide separates on-treatment SSRI/SNRI sexual side effects from post-discontinuation persistence (often called post-SSRI sexual dysfunction, or PSSD), compares official regulator warnings across the EMA, UK MHRA, Health Canada and U.S. FDA, and summarises evidence-based prescriber management options using primary regulatory and peer-reviewed sources checked on 22 October 2026. See our Medical Disclaimer.
Asked online (paraphrased): “Sertraline helped my anxiety enormously, but it takes me 45 minutes to reach a muted orgasm and my sex drive dropped. I read online threads about PSSD and panicked about stopping cold turkey—what do official medicine regulators actually say, and what options can I discuss with my doctor without wrecking my mental health?”
Safety box: why you must never stop an SSRI or SNRI abruptly
As the UK MHRA Antidepressants Expert Working Group review stresses, reading frightening forum posts sometimes pushes people to throw away their tablets overnight. Stopping an SSRI or SNRI suddenly—especially shorter-half-life drugs such as paroxetine, venlafaxine, duloxetine or sertraline—frequently triggers acute discontinuation symptoms (electric-shock “brain zaps,” dizziness, insomnia, rebound panic, severe mood crashes) and carries no evidence of protecting sexual function. Always book a non-urgent appointment with your prescriber before changing a single dose; if you ever experience thoughts of self-harm or suicide, contact emergency services or your local crisis line immediately (see Talk to a Real Clinician).
Separating four different clinical pictures: depression, on-drugTESD, withdrawal and PSSD
A 2026 clinical framework in the Journal of Sex & Marital Therapy and Medsafe pharmacovigilance reviews emphasize that four distinct processes can affect sexual function around antidepressant treatment:
- Untreated or relapsing depression and anxiety: Major depression and generalized anxiety disorder themselves strongly suppress libido, arousal and erectile/lubrication response. In some patients, sexual desire actually improves once depression lifts on treatment.
- On-drug Treatment-Emergent Sexual Dysfunction (TESD): By increasing synaptic serotonin, SSRIs and SNRIs stimulate postsynaptic 5-HT2A and 5-HT2C receptors, which dampen central dopamine and noradrenaline signalling in sexual-reward and spinal-ejaculatory pathways. In studies using structured sexual-function questionnaires (rather than spontaneous self-report), 25% to 70% of patients taking SSRIs or venlafaxine report some degree of delayed orgasm/ejaculation, anorgasmia, or lowered desire while taking the medication.
- Acute discontinuation / withdrawal fluctuations: During the weeks to early months after tapering off an SSRI or SNRI, the nervous system recalibrates receptor sensitivity; temporary fluctuations in arousal, premature ejaculation (once serotonin inhibition lifts) or muted sensation commonly settle over weeks to months.
- Post-SSRI Sexual Dysfunction (PSSD): A subset of patients report sexual symptoms that either begin during treatment and persist—or emerge upon stopping—and continue for at least 3 months to years after the drug has cleared. Characteristic features reported in the clinical literature include reduced genital tactile sensitivity (genital numbness/hypoaesthesia), pleasureless or muted orgasm (anhedonic orgasm), loss of libido, and erectile or lubrication failure in the absence of active depression.
What medicine regulators across the EU, UK, Canada and the US say on official labels
The table below compares the exact regulatory actions and label wording adopted by major health authorities.
| Regulator & jurisdiction | Date & document | Official label / safety review position on persistent symptoms | What remains unknown in regulator reviews |
|---|---|---|---|
| European Medicines Agency (EMA — EU/EEA) | June 2019 (EMA/PRAC/265212/2019, EPITT no 19277) | Mandated updated warnings in Section 4.4 of all SSRI and SNRI summaries of product characteristics (SmPCs) and patient leaflets: “SSRIs/SNRIs may cause symptoms of sexual dysfunction. There have been reports of long-lasting sexual dysfunction where the symptoms have continued despite discontinuation of SSRIs/SNRI.” | True population incidence (frequency listed as “not known — cannot be estimated from the available data”) and exact biological mechanism |
| UK MHRA (United Kingdom) | 2019 label update & 2026 EWG Report (MHRA PAR Antidepressant Review) | Adopted the 2019 SmPC/Patient Information Leaflet persistent sexual dysfunction warning across SSRIs and SNRIs; Expert Working Group recommends clear pre-treatment counselling and shared decision-making | Prospective epidemiological incidence and validated biomarker or targeted treatment for persistent cases |
| Health Canada (Canada) | 2021 Summary Safety Review (SSR00254) | Found rare reports of long-lasting sexual symptoms persisting after stopping SSRIs/SNRIs; concluded existing studies “could neither confirm, nor rule out, a causal link” and updated Canadian product monographs so healthcare professionals inform patients of the potential risk | Exact causal pathway and why a small subset of patients do not recover immediately after washout |
| U.S. Food and Drug Administration (FDA — United States) | DSM-5-TR (2022) & U.S. Prescribing Information | All U.S. SSRI/SNRI labels warn of on-treatment sexual side effects; the U.S. fluoxetine (Prozac) label notes that symptoms of sexual dysfunction “occasionally persist after discontinuation of fluoxetine treatment,” and the APA’s DSM-5-TR notes that serotonin reuptake inhibitor-induced sexual dysfunction may persist after discontinuation in some cases, though a class-wide Citizen Petition remains under review | Standardized class-wide U.S. label wording and prospective post-discontinuation incidence data |
On-treatment sexual side effects: evidence-graded options to ask your prescriber about
If you are currently taking an SSRI or SNRI and experiencing delayed orgasm, lowered desire or erectile/lubrication changes, clinical guidelines and pharmacovigilance reviews outline five evidence-based strategies your prescriber can consider—without leaving your depression or anxiety untreated:
| Prescriber strategy | How it works clinically | Evidence & practical considerations |
|---|---|---|
| 1. Rule out co-factors and wait 4–8 weeks if newly started | Mild early sexual side effects resolve spontaneously in ~10%–15% of patients after the first 4–8 weeks; clinicians also check thyroid, iron, prolactin, testosterone and relationship/stress factors | First step when symptoms are mild and the antidepressant is working well |
| 2. Supervised dose adjustment to the minimum effective dose | SSRI/SNRI sexual side effects are strongly dose-dependent | Only appropriate if your mood/anxiety is stable and your prescriber judges a lower maintenance dose safe against relapse |
| 3. Adding or switching to an antidepressant with a lower sexual-side-effect profile | Non-serotonergic or receptor-selective agents—such as bupropion (a dopamine-noradrenaline reuptake inhibitor), mirtazapine, vortioxetine, agomelatine or vilazodone—have significantly lower rates of treatment-emergent sexual dysfunction in RCTs (Medsafe) | Cochrane and RCT data support either switching to bupropion/vortioxetine or adding adjunctive bupropion when clinically suitable (bupropion is not suitable for everyone, e.g., seizure risk or certain anxiety profiles) |
| 4. Targeted addition of a PDE5 inhibitor (sildenafil or tadalafil) | Randomized controlled trials show PDE5 inhibitors significantly improve SSRI-induced erectile dysfunction and secondary orgasmic delay in men | Addresses peripheral nitric-oxide vascular response even while continuing the necessary SSRI |
| 5. Vibratory stimulation, lubricant & timing adjustments | Higher-intensity external clitoral or penile vibratory stimulation helps cross a raised serotonergic orgasm threshold; unflavoured water- or silicone-based lube fixes reduced lubrication (see Toy Materials Guide and Mismatched Libido) | Zero drug interactions; can be used immediately alongside medical review |
5 questions to bring to your prescribing clinician
- “Since starting [medication name/dose], I’ve noticed [delayed orgasm / reduced genital sensation / lower desire / erection changes]. Could we review whether this is dose-related or medication-related?”
- “Given my specific mental-health history, am I a candidate for a lower maintenance dose, adjunctive bupropion, or a cross-taper to a medication with lower sexual side effects such as bupropion, vortioxetine or mirtazapine?”
- “Would a PDE5 inhibitor or another targeted option make sense while I stay on this medication?”
- “If we ever decide in the future to stop this medication, what slow, hyperbolic tapering schedule will we use to minimize withdrawal symptoms?”
- “If sexual symptoms persist after stopping a medication, how can we log an official pharmacovigilance report (e.g., UK Yellow Card, FDA MedWatch, Canada Vigilance, or TGA) and rule out endocrine or pelvic-floor contributors?” (See also Finasteride and Sexual Side Effects and Talk to a Real Clinician.)
Sources and evidence notes
- European Medicines Agency (EMA) PRAC — New Product Information Wording: SSRIs and SNRIs — Persistent Sexual Dysfunction After Drug Withdrawal (EPITT no 19277, June 2019) (checked 22 October 2026).
- Health Canada — Summary Safety Review: SSRIs and SNRIs — Assessing the Potential Risk of Sexual Dysfunction Despite Treatment Discontinuation (checked 22 October 2026).
- UK Medicines and Healthcare products Regulatory Agency (MHRA) — Public Assessment Report: Antidepressants Expert Working Group Review (checked 22 October 2026).
- New Zealand Medsafe — MARC Report: Serotonin Reuptake Inhibitors and Persistent Sexual Dysfunction After Discontinued Treatment (checked 22 October 2026).
- Journal of Sex & Marital Therapy (Taylor & Francis, 2026) — Persistent Sexual Dysfunction After SSRIs and SNRIs: A Clinical Framework for Assessment, Counseling, and Pharmacovigilance (checked 22 October 2026).
Method & corrections: See How We Research and Corrections.
